Arch Biopartners Closes Non-Brokered Private Placement
· Financial Post
These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide1. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. Read More
Visit asg-reflektory.pl for more information.